RIVANNA Announces Alliance With Tri-anim Health Services

RIVANNA ®, developers of world-first, imaging-based medical solutions, announced they have entered into a partnership with Tri-anim Health Services, a specialty distributor of respiratory, anesthesia, and critical-care supplies, to represent and distribute the Accuro® portfolio of products in the United States.

Tri-anim is a natural distribution choice for RIVANNA as they provide effective and efficient patient care solutions, including innovative and proven specialty anesthesia products and consumables to support the vital role of the anesthesia provider.

Will Mauldin, Ph.D., co-founder, and CEO of RIVANNA, commented, “We worked together to establish this strategic partnership, and are excited to begin an alliance with Tri-anim due in part to their specialty anesthesia focus and clinical expertise. This milestone demonstrates an increasing opportunity for Accuro sales in the anesthesia market, and we are pleased to gain momentum across the United States. Accuro’s increased national expansion and continuing worldwide market adoption indicate RIVANNA’s success and the progression of our ongoing mission to elevate the standard of care.”

The Accuro spinal navigation system is designed to improve the efficiency of spinal needle guidance procedures using groundbreaking technology, including Multi-Frequency BoneEnhance® Image Reconstruction, which provides enhanced visualization of lumbar and thoracic bony anatomy, and SpineNav3D™AI-Based Spine Recognition, which provides automated identification of spinal midline, epidural space, and depth during lumber neuraxial anesthesia. This technology also supports real-time thoracic paramedian neuraxial procedures and prescribes a “needle-track” towards the interlaminar space. Relying on automated SpineNav3D™ technology, Accuro enables users with even minimal ultrasound experience to navigate the lumbar and thoracic spine and identify relevant landmarks used to compute, visualize and pinpoint the optimal needle insertion point.

Tom Metcalf, President of Tri-anim Health Services, said, “The Tri-anim team is thrilled to introduce this groundbreaking technology to an expanding market supporting spinal needle guidance procedures in the U.S., as it underpins Tri-anim’s vision to offer the most effective products and solutions to our customers. The Accuro is clinically proven to increase first-attempt success rates, especially with challenging patient anatomy, and will help anesthesia providers improve their efficiency and elevate their standard of care.”

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”